{
  "abstract": "Introduction: The present study aimed to elucidate the therapeutic efficacy and mechanistic roles of Hydroxybenzoic Acid and Lentinan in counteracting glucocorticoid-induced osteoporosis (GIOP) in mice, with a focus on bone metabolism, inflammation, and oxidative stress pathways.\n\nMethods: Sixty-eight male Swiss Albino mice were randomly assigned to seven groups: Healthy Control, Osteoporosis (methylprednisolone 10 mg/kg), Teriparatide (3 μg/kg), Low-Dose Lentinan (200 mg/kg), High-Dose Lentinan (400 mg/kg), Low-Dose HBA (50 μg/kg), and High-Dose HBA (100 μg/kg). In the study, all treatments were administered daily for a duration of 10 weeks.\n\nResults and Discussion: Methylprednisolone administration resulted in marked deterioration of bone quality, with significant reductions in 25(OH)D3, IGF-1, and increased osteocalcin, TNF-α, IL-1β, HSP-27, RANK, and RANKL expression, accompanied by severe trabecular bone loss, all treatment groups showed notable recovery, with the most pronounced restoration in teriparatide and high-dose hydroxybenzoic acid groups. Mechanistically, hydroxybenzoic acid exerted potent anti-osteoclastic effects through RANK/RANKL pathway suppression, while Lentinan enhanced osteoblastic activity and mitigated inflammatory damage. In conclusion, these results provide preclinical evidence that HBA and lentinan warrant further investigation as potential adjuncts to established anti-osteoporotic therapy in the setting of long-term glucocorticoid use.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Selcuk University",
    "Department of Histology and Embryology, Faculty of Medicine, Istanbul Aydın University",
    "Department of Pathology, Faculty of Veterinary Medicine, Harran University",
    "Department of Anatomy, Faculty of Veterinary Medicine, Harran University",
    "Department of Pharmacy, Gabriele d’Annunzio University"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 9,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Busra Soyler"
    },
    {
      "affs": [
        0
      ],
      "name": "Tugba Melike Parlak"
    },
    {
      "affs": [
        0
      ],
      "name": "Ibrahim Buyuktaskapulu"
    },
    {
      "affs": [
        1
      ],
      "name": "Muhammed Demircioglu"
    },
    {
      "affs": [
        2
      ],
      "name": "Muhammet Bahaeddin Dortbudak"
    },
    {
      "affs": [
        3
      ],
      "name": "Ali Kocyigit"
    },
    {
      "affs": [
        3
      ],
      "name": "Ismail Demircioglu"
    },
    {
      "affs": [
        4
      ],
      "name": "Annalisa Chiavaroli"
    },
    {
      "affs": [
        0
      ],
      "name": "Burak Dik"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/3yaj2074hapz0.bib",
  "cited_by": 0,
  "doi": "10.3389/fphar.2026.1957515",
  "fulltext_url": "https://www.frontiersin.org/articles/10.3389/fphar.2026.1957515/full",
  "id": "3yaj2074hapz0",
  "issns": [
    "1663-9812"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fphar.2026.1957515/full",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "RM1-950"
    ],
    [
      "openalex",
      "1312|Bone Metabolism and Diseases"
    ]
  ],
  "openalex": "W7223668692",
  "pdf_url": "https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1957515/pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-26",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/3yaj2074hapz0.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:06Z",
      "native_id": "10.3389/fphar.2026.1957515",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fphar.2026.1957515/full"
    },
    {
      "first_seen": "2026-10-30T13:47:18Z",
      "native_id": "3737d5084fde4164a286559779ca8863",
      "source": "doaj",
      "url": "https://doi.org/10.3389/fphar.2026.1957515"
    }
  ],
  "subjects": [
    {
      "field": "biochemistry",
      "origin": "openalex:1312|Bone Metabolism and Diseases",
      "subfield": "molecular-biology"
    }
  ],
  "title": "Therapeutic potential of hydroxybenzoic acid and lentinan in mitigating glucocorticoid-induced osteoporosis: an experimental study",
  "title_text": "Therapeutic potential of hydroxybenzoic acid and lentinan in mitigating glucocorticoid-induced osteoporosis: an experimental study",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T13:47:18Z",
  "url": "https://research.draconitic.com/paper/3yaj2074hapz0",
  "venue": "Frontiers in Pharmacology",
  "versions": []
}